Clinical Study

A Single 48mg Sucralose Sip Unbalances Monocyte Subpopulations and Stimulates Insulin Secretion in Healthy Young Adults

Angélica Y. Gómez-Arauz,1 Nallely Bueno-Hernández,1 Leon F. Palomera,1 Raúl Alcántara-Suárez,1 Karen L. De León,1 Lucia A. Méndez-García,1 Miguel Carrero-Aguirre,1 Aaron N. Manjarrez-Reyna,1 Camilo P. Martínez-Reyes,1 Marcela Esquivel-Velázquez,1, Alejandro Ruiz-Barranco,2 Neyla Baltazar-López,3 Sergio Islas-Andrade,1 Galileo Escobedo1,1, and Guillermo Meléndez1

1Laboratory for Proteomics and Metabolomics, Research Division, General Hospital of Mexico "Dr. Eduardo Liceaga", 06720 Mexico City, Mexico
2Clinical Nutrition Division, General Hospital of Mexico "Dr. Eduardo Liceaga", 06720 Mexico City, Mexico
3Research Coordination at Central Laboratories, General Hospital of Mexico "Dr. Eduardo Liceaga", 06720 Mexico City, Mexico

Correspondence should be addressed to Galileo Escobedo; gescobedog@msn.com and Guillermo Meléndez; melendez651@gmail.com

Received 12 December 2018; Revised 25 February 2019; Accepted 14 March 2019; Published 28 April 2019

Guest Editor: Daniel Ortuño-Sahagún

Copyright © 2019 Angélica Y. Gómez-Arauz et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Sucralose is a noncaloric artificial sweetener that is widely consumed worldwide and has been associated with alteration in glucose and insulin homeostasis. Unbalance in monocyte subpopulations expressing CD11c and CD206 hallmarks metabolic dysfunction but has not yet been studied in response to sucralose. Our goal was to examine the effect of a single sucralose sip on serum insulin and blood glucose and the percentages of classical, intermediate, and nonclassical monocytes in healthy young adults subjected to an oral glucose tolerance test (OGTT). This study was a randomized, placebo-controlled clinical trial. Volunteers randomly received 60 mL water as placebo (n = 20) or 48 mg sucralose dissolved in 60 mL water (n = 25), fifteen minutes prior to an OGTT. Blood samples were individually drawn every 15 minutes for 180 minutes for quantifying glucose and insulin concentrations. Monocyte subsets expressing CD11c and CD206 were measured at -15 and 180 minutes by flow cytometry. As compared to controls, volunteers receiving sucralose exhibited significant increases in serum insulin at 30, 45, and 180 minutes, whereas blood glucose values showed no significant differences. Sucralose consumption caused a significant 7% increase in classical monocytes and 63% decrease in nonclassical monocytes with respect to placebo controls. Pearson’s correlation models revealed a strong association of insulin with sucralose-induced monocyte subpopulation unbalance whereas glucose values did not show significant correlations. Sucralose ingestion decreased CD11c expression in all monocyte subsets and reduced CD206 expression in nonclassical monocytes suggesting that sucralose does not only unbalance monocyte subpopulations but also alter their expression pattern of cell surface molecules. This work demonstrates for the first time that a 48 mg sucralose sip increases serum insulin and unbalances monocyte subpopulations expressing CD11c and CD206 in noninsulin-resistant healthy young adults subjected to an OGTT. The apparently innocuous consumption of sucralose should be reexamined in light of these results.

1. Introduction

Noncaloric artificial sweeteners, including aspartame, acesulfame k, and sucralose, are food additives that preserve the taste of sweetness without increasing the calories of food and beverages [1]. For this reason, consumption of noncaloric artificial sweeteners is now widely spread among people from all ages and socioeconomic status worldwide [2, 3].
Nevertheless, a growing number of clinical and experimental studies have now suggested that noncaloric artificial sweeteners are linked to the development of metabolic abnormalities including insulin resistance and glucose intolerance, especially sucralose [4–8]. A seminal study demonstrated that ingestion of 48 mg sucralose significantly increases the serum values of glucose and insulin in morbidly obese subjects of both sexes subjected to a 75 g oral glucose tolerance test (OGTT) [9]. Similarly, overweight subjects that consumed sucralose prior to an OGTT exhibited a 1.2-fold elevation in the insulin peak as compared to placebo controls [10]. Therefore, the apparently innocuous effect of sucralose and others noncaloric artificial sweeteners on glucose and insulin homeostasis should be reexamined in light of this evidence.

It is now well accepted that low-grade systemic inflammation is a central player in obesity and contributes to the pathogenesis of metabolic disease, especially alteration of glucose and insulin homeostasis [11–13]. Besides being characterized by abnormally high levels of cytokines such as tumor necrosis factor alpha (TNF-alpha) and interleukin-1 beta (IL-1beta), low-grade systemic inflammation is accompanied by alteration in monocyte subpopulations [14]. In humans, circulating monocytes are sorted in three different subpopulations according to the cell surface expression of CD14 and CD16 [15]. Classical monocytes exhibit high CD14 levels and show no expression of CD16 (CD14++CD16–). The intermediate monocyte subpopulation shows high CD14 expression and also exhibit CD16 expression (CD14++CD16+) whereas nonclassical monocytes produce low CD14 levels and show expression of CD16 (CD14–CD16+) [15, 16]. Interestingly, the percentage of nonclassical monocytes has been shown to elevate in obese subjects that exhibit increased insulin resistance and metabolic syndrome [17, 18]. In the same sense, the classical monocyte subpopulation has been shown to increase in obese individuals and correlates with higher proportion of CD11c+ macrophages in the visceral adipose tissue (VAT) [19]. CD11c is a beta-2 integrin with prominent functions in cell adherence of monocytes and macrophages to vascular endothelial tissue and VAT [19, 20]. Furthermore, monocytes have been shown to express CD206 [21], a cell surface marker highly expressed in anti-inflammatory macrophages that is also associated with improved insulin sensitivity in both humans and mice [22, 23]. In this way, modulation of CD11c and CD206 expression in monocyte-macrophage lineage cells is crucial not only in typical immune functions such as cell migration and inflammation but also in obesity and insulin resistance [24]. Thus, imbalance in monocyte subpopulations expressing CD11c and CD206 hallmarks metabolic dysfunction but has not yet been studied in response to noncaloric artificial sweetener consumption such as sucralose.

The main goal of this study was to examine the effect of a single sucralose sip on the percentages of classical, intermediate, and nonclassical monocytes expressing CD11c and CD206 in healthy young adults subjected to an OGTT, while also exploring the possible relationship of monocyte subpopulations with changes in glucose and insulin homeostasis.

2. Materials and Methods

2.1. Subjects and Study Design. Forty-five healthy adult volunteers of both sexes with homeostasis model assessment (HOMA) values ≤3.8, aging between 18 and 35 years, who attended to the Department of Internal Medicine and the Laboratory for Proteomics and Metabolomics of the General Hospital of Mexico from September 2016 to April 2018 were included in the randomized, parallel-group, placebo-controlled clinical trial. All of the study participants provided written informed consent, previously approved by the Institutional Ethical Committee of the General Hospital of Mexico, which guaranteed that the study was conducted in rigorous adherence to the principles described in the 1964 Declaration of Helsinki and its posterior amendment in 2013. Subjects were excluded of the study if they had previous diagnosis of type 1 diabetes mellitus (T1D), type 2 diabetes mellitus (T2D), cardiovascular disease, acute or chronic liver disease, acute or chronic renal disease, cancer, endocrine disorders, infectious diseases, and inflammatory or autoimmune disease. We also excluded of the study to HIV-, HCV-, and HBV-seropositive patients, pregnant or lactating women, and individuals with anti-inflammatory, antiaggregant, antihypertensive, and immunomodulatory medication including nonsteroidal anti-inflammatory drugs. All participants included in the study had 8-10 hr overnight fasting before being subjected to the OGTT.

2.2 Oral Glucose Tolerance Test. The present study was a randomized, parallel-group, placebo-controlled clinical trial, where volunteers randomly drank 60 mL water as placebo (n = 20) or 48 mg sucralose dissolved in 60 mL water (n = 25), fifteen minutes prior to an OGTT. A regular “light” beverage available in the market approximately contains 48 mg sucralose. For this reason, we decided to use 48 mg sucralose dissolved in 60 mL water, as previously reported [9]. Each participant had up to three minutes to finish the sip of water or sucralose. Starting with oral glucose load at min zero, venous blood samples were drawn from all study subjects every 15 min for 180 min for quantifying the blood levels of glucose and insulin. Additional blood samples were also collected at -15 and 180 min for white blood cell isolation and characterization of monocyte subpopulations by flow cytometry.

2.3. Anthropometric and Biochemical Measurements. Body mass index (BMI), waist circumference, and blood pressure were measured in all study volunteers. Serum levels of insulin were measured in triplicate by the enzyme-linked immunosorbent assay (ELISA) following the manufacturer’s instructions (Abnova Corporation, Taiwan). Serum levels of glucose were measured in triplicate by the glucose oxidase assay, following the manufacturer’s instructions (Megazyme International, Ireland). The HOMA index was individually calculated by multiplying glucose concentration (mmol/L) by insulin concentration (mU/L) and then divided by 22.5. The cut-off point for HOMA index was established according to studies previously validated in a Mexican population [25]. Total cholesterol, low-density lipoproteins (LDL), high-
density lipoproteins (HDL), and triglyceride levels were measured in triplicate by enzymatic assays following the manufacturer’s instructions (Roche Diagnostics, Mannheim, Germany). Glycated hemoglobin (HbA1c), blood urea nitrogen (BUN), serum creatinine, and hematric biometry were determined by standard laboratory assays.

2.4. Flow Cytometry. Isolation of white blood cells was performed by centrifuging blood samples previously collected in tubes containing EDTA (Vacutainer™, BD Diagnostics, NJ, USA) at 1800 g for 10 min. Then, white blood cells were placed in 1.6 mL pyrogen-free Eppendorf tubes containing 1 mL ACK Lysing Buffer (Life Technologies, USA) and incubated at 4°C for 5 min. Afterward, cell suspension was centrifuged at 1800 g/4°C for 10 min and cell pellets washed twice with PBS 1x (Sigma-Aldrich, Mexico). After an additional centrifugation step and removal of the supernatant, cell pellets were resuspended in 50 μL PBS 1x (Sigma-Aldrich, Mexico). Immediately after, 3 μL Human TruStain Reagent (BioLegend Inc., USA) was added to $2 \times 10^5$ white blood cells and then incubated for 10 min at 4°C. Then, each cell suspension was incubated with anti-CD14 PE/Cy7, anti-CD16 FITC, anti-CD11c APC, and anti-CD206 PE (BioLegend Inc., USA) for 30 min at 4°C. Flow cytometry analysis was performed on a FACSCanto II flow cytometer by using the BD FACSDiva™ software 6.0 (BD Biosciences, Mexico), acquiring $1 \times 10^5$ monocyte events per test in duplicate.

2.5. Gating Strategy for Flow Cytometry. White blood cells were gated for singlets on a forward scatter height/forward scatter area density plot. Afterward, areas corresponding to lymphocyte, polymorphonuclear leukocyte, and monocyte cell populations were clearly revealed and gated on a FSC-A/side scatter area plot. The monocyte gate was then selected for detection of living monocytes by using the Live/Dead Aqua Stain (Thermo Fisher Scientific Inc., USA) and posterior measurement of CD14, CD16, CD11c, and CD206 exclusively on this immune cell population. In this way, we deliberately excluded any other CD14-CD16-CD11c-CD206 signal coming from a different cellular source than monocytes. Monocyte subpopulations were then characterized according to the cell surface expression of CD14 and CD16 as follows: CD14-`CD16’, classical monocytes; CD14-`CD16’, intermediate monocytes; and CD14-`CD16’, nonclassical monocytes.

2.6. Statistics. Normality of data distribution was estimated by the Shapiro-Wilk test. The Student $T$-test was used to compare the placebo and sucralose groups regarding age, BMI, waist circumference, systolic and diastolic blood pressure, blood glucose, glycated hemoglobin percentage, serum insulin, HOMA-IR, total cholesterol, LDL, HDL, triglycerides, blood urea nitrogen, serum creatinine, and hematric biometry, and data were expressed as mean ± standard deviation. The mean fluorescence intensity (MFI) of CD11c and CD206 as well as the percentages of classical, intermediate, and nonclassical monocytes at -15 and 180 min of the OGTT were analyzed using two-tailed 2-way ANOVA with correction for multiple comparisons by means of the Bonferroni multiple comparison test, and data were expressed as media ± standard deviation. Differences in the mean values of glucose and insulin at -15, 0, 15, 30, 45, 60, 75, 90, 105, 120, and 180 min of the OGTT, between volunteers enrolled in placebo or sucralose groups, were estimated by means of two-tailed 2-way ANOVA with correction for multiple comparisons using the Bonferroni multiple comparison test. Furthermore, the women/men proportion in placebo and sucralose groups was analyzed by means of the chi-squared test and data expressed as absolute values. Pearson’s correlation coefficients were estimated for examining the statistical correlation of classical, intermediate, and nonclassical monocytes with glucose and insulin and expressed as coefficients $(r)$ and $P$ values. Differences were considered significant when $P < 0.05$. Statistical analyses were performed by means of the GraphPad Prism 6.01 software (GraphPad Software, La Jolla, CA 92037 USA).

3. Results

There were no differences between subjects receiving placebo $(n = 20)$ or sucralose $(n = 25)$ in terms of demographic, metabolic, and hematric characteristics, including gender, age, BMI, HOMA-IR, lipid profile, renal function, and monocytes per microliter of blood (Table 1).

Blood glucose values showed no significant differences in subjects receiving placebo or sucralose all along the oral glucose tolerance test (Figure 1(a)). On the contrary, volunteers that received 48 mg sucralose prior glucose load showed a significant 1.3-fold increase in the serum levels of insulin at 30 min as compared to subjects drinking water as placebo $(P = 0.041)$ (Figure 1(b)). At 45 min, subjects receiving sucralose exhibited a significant 1.4-fold elevation in serum insulin with respect to placebo controls $(P = 0.046)$ (Figure 1(b)). At 180 min, subjects that received sucralose showed a significant 2-fold increase in the serum levels of insulin as compared to placebo controls $(P = 0.048)$ (Figure 1(b)).

Representative dot plots illustrating monocyte subpopulations in subjects that received placebo or sucralose are shown in Figure 2. At the beginning of the oral glucose tolerance test (-15 min), no differences were seen in the percent-ages of classical, intermediate, and nonclassical monocytes in subjects receiving placebo or sucralose (Figure 2(a) versus 2c, respectively). At the end of the experiment (180 min), the percentage of classical monocytes increased in subjects that received 48 mg sucralose as compared to placebo controls (Figure 2(d) versus 2b, respectively). In contrast, the nonclassical monocyte percentage was reduced in subjects exposed to sucralose with respect to placebo controls (Figure 2(d) versus 2b, respectively). Quantification of monocyte subpopulation percentages confirmed a significant 7% increase in the number of classical monocytes from subjects that received sucralose in comparison to controls receiving placebo $(P = 0.0028)$ (Figure 2(e)). On the other side, the nonclassical monocyte percentage exhibited a significant 63% reduction in subjects exposed to sucralose with respect to placebo controls $(P < 0.0001)$ (Figure 2(e)). No significant differences were found in the percentage of intermediate monocytes in subjects that received placebo or sucralose.
Analysis of Pearson’s correlation coefficients showed no significant associations of monocyte subpopulations with blood glucose (Table 2). On the contrary, serum insulin showed a positive relationship with classical monocytes \((r = 0.41, P = 0.02)\), whereas it also exhibited a strong inverse association with nonclassical monocytes \((r = -0.42, P = 0.01)\) (Table 2).

At the beginning of the OGTT, CD11c expression in classical, intermediate, and nonclassical monocytes showed no significant differences in subjects receiving placebo or sucralose (Figure 3(a)). At 180 min, CD11c expression was significantly reduced in intermediate and nonclassical monocytes of subjects receiving sucralose as compared to placebo controls \((P = 0.0012\) and \(P = 0.0064\), respectively) (Figure 3(a)). CD11c expression also exhibited a significant reduction in intermediate and nonclassical monocytes of subjects exposed to sucralose at the beginning \((-15\) min) and at the end \((180\) min) of the OGTT \((P = 0.0004\) and \(P = 0.0001\), respectively) (Figure 3(a)). In classical monocytes, CD11c expression significantly diminished in the sucralose group at the beginning \((-15\) min) and at the end \((180\) min) of the OGTT \((P = 0.0008)\) (Figure 3(a)). At the beginning of the OGTT, CD206 expression in classical, intermediate, and nonclassical monocytes showed no significant differences in subjects that received placebo or sucralose (Figure 3(b)). At 180 min, CD206 expression was significantly reduced in nonclassical monocytes of volunteers that received sucralose as compared to placebo controls \((P = 0.0098)\) (Figure 3(b)).

4. Discussion

Noncaloric artificial sweeteners are now consumed by millions of people from all ages, gender, and socioeconomic status around the globe [26]. However, sucralose and other noncaloric artificial sweeteners have been now linked to disturbances in glucose and insulin homeostasis in both animal models and humans [5–9]. For this reason, it is still of great relevance to keep characterizing the possible deleterious effects of sucralose on human metabolism in randomized, parallel-group, placebo-controlled clinical trials.

In this study, we found that one single 48 mg sip of sucralose, a sucralose amount that is contained in numerous “light” beverages available in the market, increases serum insulin but not glucose in age- and sex-matched healthy young adults subjected to an OGTT. These data appear contrary to previous information showing that a similar amount of sucralose is able to elevate both insulin and glucose in morbidly obese individuals receiving a glucose load [9]. Nevertheless, this apparently contradictory evidence should

Table 1: Demographic, metabolic, and hematic characteristics of the study population.

| Parameters                      | Placebo                  | Sucralose                  | \(P\) value |
|---------------------------------|--------------------------|----------------------------|-------------|
| Gender (W/M)                    | 8/12                     | 8/17                       | 0.288       |
| Age (years)                     | 21.55 ± 2.18             | 22.36 ± 2.99               | 0.158       |
| BMI (kg/m²)                     | 24.58 ± 3.63             | 23.67 ± 2.88               | 0.177       |
| Waist circumference (cm)        | 82.27 ± 8.44             | 78.57 ± 8.37               | 0.074       |
| SBP (mmHg)                      | 111.10 ± 8.16            | 113.70 ± 13.91             | 0.225       |
| DBP (mmHg)                      | 70.75 ± 5.77             | 71.16 ± 7.33               | 0.419       |
| Blood glucose (mg/dL)           | 88.20 ± 6.65             | 89.96 ± 5.68               | 0.172       |
| HbA1c (%)                       | 5.26 ± 0.24              | 5.23 ± 0.19                | 0.497       |
| Serum insulin (μU/L)            | 7.94 ± 2.91              | 8.31 ± 2.82                | 0.335       |
| HOMA-IR (a.u.)                  | 1.75 ± 0.70              | 1.85 ± 0.65                | 0.298       |
| Total cholesterol (mg/dL)       | 166.70 ± 31.21           | 168.60 ± 32.53             | 0.418       |
| LDL (mg/dL)                     | 102.10 ± 28.92           | 99.80 ± 26.60              | 0.393       |
| HDL (mg/dL)                     | 43.05 ± 10.60            | 44.40 ± 12.20              | 0.349       |
| Triglycerides (mg/dL)           | 111.20 ± 58.10           | 118.20 ± 102.70            | 0.392       |
| BUN (mg/dL)                     | 22.40 ± 6.98             | 23.71 ± 5.95               | 0.249       |
| Serum creatinine (mg/dL)        | 0.82 ± 0.13              | 0.78 ± 0.13                | 0.165       |
| Hematocrit (%)                  | 45.63 ± 3.53             | 44.04 ± 4.37               | 0.097       |
| Total leukocytes \((10^3/μL)\) | 6.38 ± 1.49              | 6.05 ± 0.96                | 0.187       |
| Monocytes \((10^7/μL)\)        | 0.43 ± 0.11              | 0.39 ± 0.10                | 0.109       |
| Monocytes (%)                   | 6.94 ± 1.77              | 6.42 ± 1.33                | 0.134       |

Data are expressed as media ± standard deviation. The Shapiro-Wilk test was used to estimate normality in data distribution. Significant differences were estimated by means of performing the Student T-test with the exception of women/men proportion that was estimated by means of the chi-squared test. Differences were considered significant when \(P < 0.05\). Abbreviations: W: women; M: men; BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; HbA1c: glycated hemoglobin; HOMA-IR: homeostatic model assessment of insulin resistance; LDL: low-density lipoprotein; HDL: high-density lipoprotein; BUN: blood urea nitrogen; a.u.: arbitrary units.
be examined in light of previous information showing that healthy young adults with no insulin resistance have the ability to increase insulin secretion and thus effectively decrease the excess of blood glucose [27, 28]. In contrast, numerous studies have consistently shown that non-diabetic morbidly obese subjects exposed to a glucose load can clearly increase insulin secretion without achieving blood glucose clearance due to a marked insulin resistance [29–32]. In this scenario, it is feasible to suppose that sucralose consumption may have differential effects on healthy young adults and morbidly obese subjects due to the presence of insulin resistance. In other words, sucralose ingestion may stimulate insulin secretion and, in this way, reduce glucose levels in healthy young adults but not morbidly obese subjects that show higher levels of insulin resistance and thus glucose intolerance. The fact that sucralose is able to stimulate directly insulin secretion in healthy young adults receiving a 75 g glucose load.

Another phenomenon captured in our study involves the possible mechanism by which sucralose exerts its effects on classical and nonclassical monocytes in healthy young adults. Sweet taste of sucralose and other caloric and non-caloric sweeteners is mediated by G protein-coupled receptors (GPCR) T1R1, T1R2, and T1R3 [38]. Sweet taste receptors were firstly described in the gut [39], enteroendocrine cells, and pancreas [40]. Nevertheless, T1R3 has been also indentified in mouse peritoneal macrophages [41]. Notably, in vitro exposure of T1R3 to trehalose (a disaccharide consisting of two molecules of glucose) has been shown to associate with suppression of TNF-alpha and IL-1beta production, accompanied by reduced expression of IL-10, which supports the role of sucralose in modulating immune cell activation [5].

As mentioned before, low-grade activation of monocytes and macrophages has been shown to associate with the development of hyperinsulinemia, glucose intolerance, and insulin resistance [17–19, 34]. In this sense, it is well known that nutritive sweeteners such as sucrose or glucose exert the ability to increase TNF-alpha and IL-1beta expression and downregulate interleukin-10 (IL-10) production in human monocyte-derived macrophages in vitro [35, 36]. However, the effect of noncaloric artificial sweeteners on immune cells remains elusive. A previous study showed that exposure of human whole blood leukocytes to sucralose is able to suppress interleukin-6 (IL-6) and IL-10 secretion in vitro, even in the presence of phytohemagglutinin (PHA) or lipopolysaccharide (LPS) [37]. Likewise, the CD3+ T cell percentage has been shown to increase in Peyer’s patches and lamina propria of mice receiving sucralose in drinking water [5]. Moreover, CD3+ T cells in Peyer’s patches also showed elevation in TNF-alpha and interferon-gamma (IFN-gamma) production, accompanied by reduced expression of IL-10, which supports the role of sucralose in modulating immune cell activation [5]. Concurring with previous information, our findings show for the first time that a single sip of sucralose significantly increases the percentage of classical monocytes and reduces the nonclassical monocyte subpopulation in healthy young adults receiving a 75 g glucose load.

**Figure 1:** Blood levels of glucose and insulin in healthy young adults that received sucralose or placebo during an oral glucose tolerance test. Volunteers randomly received 60 mL water as placebo (n = 20) or 48 mg sucralose dissolved in 60 mL water (n = 25) 15 min prior to a 75 g oral glucose tolerance test (OGTT). Starting with glucose load at minute zero, venous blood samples were drawn from all study subjects every 15 min for 180 min for quantifying the blood levels of glucose and insulin. (a) Blood glucose did not show significant changes in subjects receiving placebo or sucralose all along the OGTT. (b) Serum insulin significantly increased at 30, 45, and 180 min in volunteers that received sucralose as compared to placebo controls. Timing of stimulation with sucralose, placebo, or glucose is shown on the graphic by black arrows. The placebo group is shown in open circles, whereas the sucralose group can be seen in closed circles. Data are expressed as media ± standard error. Significant differences between subjects receiving placebo or sucralose were estimated on each point of the OGTT by performing two-tailed 2-way ANOVA with correction for multiple comparisons by means of the Bonferroni multiple comparisons test. Significant differences are indicated by asterisks. Differences were considered significant when P < 0.05.
Figure 2: Percentages of classical, intermediate, and nonclassical monocytes in healthy young adults that received sucralose or placebo at the beginning and at the end of an oral glucose tolerance test. Representative flow cytometry dot plots showing the percentages of classical (CM), intermediate (IM), and nonclassical monocytes (NCM) in the placebo group at the beginning (a) and at the end (b) of the oral glucose tolerance test (OGTT). Representative dot plots showing the percentages of CM, IM, and NCM in the sucralose group at the beginning and at the end of the OGTT can be seen in (c) and (d), respectively. (e) As expected, quantification of monocyte subpopulation percentages showed no differences between placebo and sucralose groups at the beginning of the OGTT (-15 min). At 180 min, the CM percentage significantly increased whereas the NCM percentage decreased in volunteers that received 48 mg sucralose as compared to subjects that received water as placebo. No significant differences were seen in the IM percentage. The placebo group is shown in open bars, whereas the sucralose group can be seen in closed bars. Monocytes were gated on a CD14⁺CD16⁻ dot plot to identify monocyte subpopulations as follows: CD14⁺CD16⁻, classical monocytes; CD14⁺CD16⁺, intermediate monocytes; and CD14⁺CD16⁻, nonclassical monocytes. Data are expressed as media ± standard deviation. Significant differences between placebo and sucralose groups were estimated by performing two-tailed, 2-way ANOVA followed by the Bonferroni multiple comparisons test. Significant differences are indicated by asterisks. Differences were considered significant when P < 0.05.
expression in murine macrophages [41]. It is then feasible to speculate that sucralose may alter CD14 and CD16 expression via T1R3, which would lead to unbalance in the percentages of classical and nonclassical monocytes. However, we still need to measure sweet taste receptor expression on human monocyte subpopulations to draw major conclusions regarding this point.

Another possible mechanism by which sucralose may orchestrate dynamic changes in classical and nonclassical monocyte subsets involves the probable role of serum insulin. In our study, increase in serum insulin was importantly correlated with elevation of classical monocytes and reduction of nonclassical monocytes only in volunteers that drank sucralose but not placebo. Devevre and coworkers previously demonstrated that serum insulin is significantly associated with classical, intermediate, and nonclassical monocyte subpopulations of morbidly obese patients with insulin resistance [18]. Moreover, another study showed that insulin is able to

---

**Table 2: Statistical correlations of monocyte subpopulations with blood levels of glucose and insulin in placebo and sucralose groups.**

|                    | Placebo       | Suzcralose    | Placebo       | Suzcralose    |
|--------------------|---------------|---------------|---------------|---------------|
| Classical monocyte (%) | 0.24, 0.12    | 0.35, 0.06    | 0.19, 0.14    | 0.25, 0.14    |
| Intermediate monocyte (%) | -0.15, 0.28   | -0.25, 0.13   | -0.20, 0.16   | 0.06, 0.38    |
| Nonclassical monocyte (%) | -0.20, 0.18   | -0.24, 0.14   | -0.37, 0.06   | 0.12, 0.27    |

For classical monocyte: 0.24, 0.01, 0.31, -0.36; for intermediate monocyte: 0.12, 0.46, 0.08, 0.06; and for nonclassical monocyte: 0.35, 0.10, 0.21, 0.04. Coefficients (r) and P values were calculated by the Pearson correlation model. The correlation level was considered significant when P < 0.05. Significant associations are marked in italic.

---

**Figure 3:** Cell surface expression of CD11c and CD206 in classical, intermediate, and nonclassical monocytes of healthy young adults that received sucralose or placebo at the beginning and at the end of an oral glucose tolerance test. (a) As expected, CD11c expression showed no differences between placebo and sucralose groups at the beginning (-15 min) of the oral glucose tolerance test (OGTT). At 180 min, CD11c expression significantly decreased in intermediate monocytes (IM) and nonclassical monocytes (NCM) of subjects that received 48 mg sucralose as compared to placebo controls. When comparing -15 and 180 min, classical monocytes (CM), IM, and NCM showed decreased CD11c expression in volunteers receiving sucralose. (b) CD206 expression showed no differences in subjects receiving placebo or sucralose at the beginning of the OGTT (-15 min). At 180 min, CD206 expression significantly decreased in the NCM subpopulation of subjects that received sucralose as compared to placebo controls. The placebo group is shown in open bars, whereas the sucralose group can be seen in closed bars. Monocytes were gated on a CD14+CD16+ dot plot to identify CD14++CD16− classical monocytes, CD14+CD16+ intermediate monocytes, and CD14−CD16− nonclassical monocytes and then measure the mean fluorescence intensity (MFI) of CD11c and CD206 on each monocyte subset. Data are expressed as media ± standard deviation. Significant differences between subjects receiving placebo or sucralose were estimated by performing two-tailed, 2-way ANOVA followed by the Bonferroni multiple comparisons test. Significant differences are indicated by asterisks. Differences were considered significant when P < 0.05.
induce protein kinase B (AKT) phosphorylation in both human classical and nonclassical monocyte subsets in a dose-dependent fashion in vitro [42]. Furthermore, Bunn and coworkers also reported that insulin boosts the palmitate-induced TNF-alpha and IL-6 expression in human monocytes in vitro [43]. Taking into account that (1) sucralose can directly stimulate pancreatic insulin secretion via T1R2 and T1R3 [33] and (2) insulin is able to regulate human monocyte activity [42, 43], it is then reasonable to suppose that serum insulin may directly modify the percentages of classical and nonclassical monocytes in subjects receiving sucralose but not placebo. Although plausible, it is a speculative notion that may open new avenues to investigate in vivo the effects of sucralose on immune cells. In parallel, our results show that sucralose consumption associates with low CD11c expression in all monocyte subsets and suggest alteration of the migratory capacity of these cells. However, such a hypothesis needs to be experimentally tested before drawing major conclusions regarding the effect of sucralose on the monocyte migratory capacity. To this respect, it has been previously reported that trehalose ingestion reduces CD11c expression in the colonic mucosa of mice treated with 2,4,6-trinitrobenzenesulfonic acid (TNBS), which in turn was associated with less infiltration of immune cells and improvement of intestinal inflammation [45]. However, to the best of our knowledge this is the first study reporting that sucralose consumption is able to decrease CD11c expression in human monocytes, a notion that may open new avenues to investigate the effect of sucralose on immune cells. In parallel, our findings also show that sucralose consumption associates with low expression levels of CD206 in classical monocytes. Since CD206 is a cell surface marker related to the anti-inflammatory ability of mononuclear cells, it is thus feasible to speculate that sucralose ingestion may associate with increased proinflammatory capacity of human monocytes. As mentioned above, Rosales-Gomez and collaborators recently demonstrated that sucralose consumption exerts proinflammatory effects on mouse CD3⁺ T cells by rising TNF-alpha and IFN-gamma expression and reducing the expression of IL-10 [5]. Similarly, Bunn and coworkers found increased expression of the proinflammatory markers TNF-alpha and nitric-oxide synthase 2 (NOS2) in the liver of mice receiving sucralose in the drinking water [46]. Present evidence concurs with our findings and supports the idea that sucralose may exert proinflammatory actions on nonclassical monocytes by decreasing CD206 expression. Nevertheless, we want to state that we still did not conduct any experimental in vitro study that firmly supports a direct role of sucralose on the anti-inflammatory activity of monocyte subsets and we are unable to draw solid conclusions regarding this topic at this time. Therefore, further in vitro studies are needed to characterize the possible effect of sucralose as a nonprototypic proinflammatory signal able to decrease CD206 expression in human monocytes.

It is worth mentioning that this study has some limitations including a possible participation of the sucralose sweet taste that may modify insulin secretion via the central nervous system as well the limited number of participants in each group. The amendment of these limitations (i.e., by using capsules containing sucralose) will bring more solid data to study the effect of sucralose on human metabolism and immunology.

5. Conclusions

This work demonstrates that a single sip of 48 mg sucralose increases the serum levels of insulin in age- and sex-matched non-insulin-resistant young adults subjected to an OGTT. Sucralose consumption was not only related to elevated levels of insulin but also increased proportion of classical monocytes and reduced percentage of nonclassical monocytes that in turn showed low expression levels of CD11c and CD206. Present results expand on the body of work that links sucralose consumption with unbalance of immune cell populations and alteration of insulin homeostasis. This work is relevant since the amount of sucralose studied here is contained in numerous “light” beverages available in the market and encourages further research focused on exploring the potential long-term impact of noncaloric artificial sweeteners on insulin metabolism and immune response in humans.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this article.

Authors’ Contributions

Angélica Y. Gómez-Arauz, and Nallely Bueno-Hernández equally contributed to this work.

Acknowledgments

This work was supported by grant no. 261575 from the Fondo Sectorial de Investigación y Desarrollo en Salud y Seguridad Social SS/IMSS/ISSSTE/CONACYT-México to G Meléndez and grant no. 286209 from the Fondo Sectorial de Investigación para la Educación-CONACYT-México to G Escobedo, and is a component of the M.Sc. requirements of A-Y Gómez-Arauz in the Posgrado en Ciencias Médicas, Odontológicas y de la Salud de la Universidad Nacional...
Autónoma de México. Dr. Blair Brown from the Medical School of the University of Minnesota corrected the English version of the manuscript. Authors thank the Flow Cytometry core facility from "Coordinación de Investigación en Salud" at "Centro Médico Nacional, Siglo XXI" of IMSS for instrumentation.

References

[1] E. Palkowska-Gozdzik, A. Bigos, and D. Rosolowska-Huszcz, "Type of sweet flavour carrier affects thyroid axis activity in male rats," European Journal of Nutrition, vol. 57, no. 2, pp. 773–782, 2018.

[2] P. J. Rogers, P. S. Hogenkamp, C. de Graaf et al., "Does low-energy sweetener consumption affect energy intake and body weight? A systematic review, including meta-analyses, of the evidence from human and animal studies," International Journal of Obesity, vol. 40, no. 3, pp. 381–394, 2016.

[3] S. E. Swithers, "Artificial sweeteners are not the answer to childhood obesity," Appetite, vol. 93, pp. 85–90, 2015.

[4] T. Feehley and C. R. Nagler, "Health: the weighty costs of non-caloric sweeteners," Nature, vol. 514, no. 7521, pp. 176–177, 2014.

[5] C. A. Rosales-Gomez, B. E. Martinez-Carrillo, A. A. Resendiz-Albor et al., "Chronic consumption of sweeteners and its effect on glycaemia, cytokines, hormones, and lymphocytes in GALT in CD1 mice," BioMed Research International, vol. 2018, Article ID 1345282, 15 pages, 2018.

[6] A. Lertrit, S. Srimachai, S. Saetung et al., "Effects of sucralose on insulin and glucagon-like peptide-1 secretion in healthy subjects: a randomized, double-blind, placebo-controlled trial," Nutrition, vol. 55–56, pp. 125–130, 2018.

[7] J. Suez, T. Korem, D. Zeevi et al., "Artificial sweeteners induce glucose intolerance by altering the gut microbiota," Nature, vol. 514, no. 7521, pp. 181–186, 2014.

[8] K. I. Rother, E. M. Conway, and A. C. Sylvetsky, "How non-nutritive sweeteners influence hormones and health," Trends in Endocrinology & Metabolism, vol. 29, no. 7, pp. 455–467, 2018.

[9] M. Y. Pepino, C. D. Tiemann, B. W. Patterson, B. M. Wice, and S. Klein, "Sucralose affects glycemic and hormonal responses to an oral glucose load," Diabetes Care, vol. 36, no. 9, pp. 2530–2535, 2013.

[10] A. C. Sylvetsky, R. J. Brown, J. E. Blau, M. Walter, and K. I. Rother, "Hormonal responses to non-nutritive sweeteners in water and diet soda," Nutrition & Metabolism, vol. 13, no. 1, p. 71, 2016.

[11] P. Gonzalez-Muniesa, M. A. Martinez-Gonzalez, F. B. Hu et al., "Obesity," Nature Reviews Disease Primers, vol. 3, article 17034, 2017.

[12] C. Herder, S. Schneitler, W. Rathmann et al., "Low-grade inflammation, obesity, and insulin resistance in adolescents," The Journal of Clinical Endocrinology & Metabolism, vol. 92, no. 12, pp. 4569–4574, 2007.

[13] C. N. Lumeng and A. R. Saltiel, "Inflammatory links between obesity and metabolic disease," The Journal of Clinical Investigation, vol. 121, no. 6, pp. 2111–2117, 2011.

[14] R. V. Considine, "Activated monocytes: yet another link between systemic inflammation and obesity," The Journal of Clinical Endocrinology & Metabolism, vol. 99, no. 7, pp. 2347–2349, 2014.

[15] R. Mukherjee, P. Kanti Barman, P. Kumar Thatoi, R. Tripathy, B. Kumar Das, and B. Ravindran, "Non-classical monocytes display inflammatory features: validation in sepsis and systemic lupus erythematosus," Scientific Reports, vol. 5, no. 1, article 13886, 2015.

[16] L. Ziegler-Heitbrock, "Blood monocytes and their subsets: established features and open questions," Frontiers in Immunology, vol. 6, p. 423, 2015.

[17] J. L. Grun, A. N. Manjarrez-Reyna, A. Y. Gomez-Arauz et al., "High-density lipoprotein reduction differentially modulates to classical and nonclassical monocyte subpopulations in metabolic syndrome patients and in LPS-stimulated primary human monocytes in vitro," Journal of Immunology Research, vol. 2018, Article ID 2737040, 12 pages, 2018.

[18] E. F. Devevre, M. Renovato-Martins, K. Clement, C. Sautes-Fridman, I. Cremer, and C. Poitou, "Profiling of the three circulating monocyte subpopulations in human obesity," The Journal of Immunology, vol. 194, no. 8, pp. 3917–3923, 2015.

[19] K. Wouters, K. Gaens, M. Bijnen et al., "Circulating classical monocytes are associated with CD11c+ macrophages in human visceral adipose tissue," Scientific Reports, vol. 7, no. 1, article 42665, 2017.

[20] H. Wu, X. D. Perrard, Q. Wang et al., "CD11c expression in adipose tissue and blood and its role in diet-induced obesity," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 30, no. 2, pp. 186–192, 2010.

[21] W. D. Cornwell, V. Kim, X. Fan et al., "Activation and polarization of circulating monocytes in severe chronic obstructive pulmonary disease," BMC Pulmonary Medicine, vol. 18, no. 1, p. 101, 2018.

[22] M. D. Kristensen, M. T. Lund, M. Hansen et al., "Macrophage area content and phenotype in hepatic and adipose tissue in patients with obesity undergoing roux-en-Y gastric bypass," Obesity, vol. 25, no. 11, pp. 1921–1931, 2017.

[23] D. Liu, F. E. Morales, H. B. IglayReger et al., "Expression of macrophage genes within skeletal muscle correlates inversely with adiposity and insulin resistance in humans," Applied Physiology, Nutrition, and Metabolism, vol. 43, no. 2, pp. 187–193, 2018.

[24] J. M. Wentworth, G. Naselli, W. A. Brown et al., "Pro-inflammatory CD11c+CD206+ adipose tissue macrophages are associated with insulin resistance in human obesity," Diabetes, vol. 59, no. 7, pp. 1648–1656, 2010.

[25] H. Q. Qu, Q. Li, A. R. Rentfro, S. P. Fisher-Hoch, and J. B. McCormick, "The definition of insulin resistance using HOMA-IR for Americans of Mexican descent using machine learning," PLoS One, vol. 6, no. 6, article e21041, 2011.

[26] V. Purohit and S. Mishra, "The truth about artificial sweeteners – are they good for diabetics?", Indian Heart Journal, vol. 70, no. 1, pp. 197–199, 2018.

[27] K. Takahashi, H. Nakamura, H. Sato, H. Matsuda, K. Takada, and T. Tsuji, "Four plasma glucose and insulin responses to a 75 g OGTT in healthy young Japanese women," Journal Diabetes Research, vol. 2018, article 5742497, 7 pages, 2018.

[28] D. Young-Hyman, D. G. Schlundt, L. Herman, F. De Luca, and D. Counts, "Evaluation of the insulin resistance syndrome in 5- to 10-year-old overweight/obese African-American children," Diabetes Care, vol. 24, no. 8, pp. 1359–1364, 2001.

[29] A. Algloban, M. Alalfi, and M. Khan, "Mechanism linking diabetes mellitus and obesity," Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, vol. 7, pp. 587–591, 2014.
[30] A. C. Meyer-Gerspach, L. Cajacob, D. Riva et al., “Mechanisms regulating insulin response to intragastric glucose in lean and non-diabetic obese subjects: a randomized, double-blind, parallel-group trial,” *PLoS One*, vol. 11, no. 3, article e0150803, 2016.

[31] M. E. Röder, D. Porte Jr., R. S. Schwartz, and S. E. Kahn, “Disproportionately elevated proinsulin levels reflect the degree of impaired β-cell secretory capacity in patients with noninsulin-dependent diabetes mellitus,” *The Journal of Clinical Endocrinology & Metabolism*, vol. 83, no. 2, pp. 604–608, 1998.

[32] P. A. Velasquez-Meyer, P. A. Cowan, K. L. Arheart et al., “Suppression of insulin secretion is associated with weight loss and altered macronutrient intake and preference in a subset of obese adults,” *International Journal of Obesity*, vol. 27, no. 2, pp. 219–226, 2003.

[33] Y. Nakagawa, M. Nagasawa, S. Yamada et al., “Sweet taste receptor expressed in pancreatic β-cells activates the calcium and cyclic AMP signaling systems and stimulates insulin secretion,” *PLoS One*, vol. 4, no. 4, article e5106, 2009.

[34] J. F. Ferguson, R. Y. Shah, R. Shah, N. N. Mehta, M. R. Rickels, and M. P. Reilly, “Activation of innate immunity modulates insulin sensitivity, glucose effectiveness and pancreatic β-cell function in both African ancestry and European ancestry healthy humans,” *Metabolism*, vol. 64, no. 4, pp. 513–520, 2015.

[35] K. Moganti, F. Li, C. Schmuttermair et al., “Hyperglycemia induces mixed M1/M2 cytokine profile in primary human monocyte-derived macrophages,” *Immunobiology*, vol. 222, no. 10, pp. 952–959, 2017.

[36] I. Torres-Castro, U. D. Arroyo-Camarena, C. P. Martinez-Reyes et al., “Human monocytes and macrophages undergo M1-type inflammatory polarization in response to high levels of glucose,” *Immunology Letters*, vol. 176, pp. 81–89, 2016.

[37] F. Rahiman and E. J. Pool, “The in vitro effects of artificial and natural sweeteners on the immune system using whole blood culture assays,” *Journal of Immunoassay and Immunochemistry*, vol. 35, no. 1, pp. 26–36, 2014.

[38] M. O. Welcome, N. E. Mastorakis, and V. A. Pereverzev, “Sweet taste receptor signaling network: possible implication for cognitive functioning,” *Neurology Research International*, vol. 2015, Article ID 606479, 13 pages, 2015.

[39] D. Hofer, B. Puschel, and D. Drenckhahn, “Taste receptor–like cells in the rat gut identified by expression of alpha-gustducin,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 93, no. 13, pp. 6631–6634, 1996.

[40] I. Kojima and Y. Nakagawa, “The role of the sweet taste receptor in enteroendocrine cells and pancreatic β-cells,” *Diabetes & Metabolism Journal*, vol. 35, no. 5, pp. 451–457, 2011.

[41] K. Taya, K. Hirose, and S. Hamada, “Trehalose inhibits inflammatory cytokine production by protecting IkB-α reduction in mouse peritoneal macrophages,” *Archives of Oral Biology*, vol. 54, no. 8, pp. 749–756, 2009.

[42] M. M. Thewissen, J. van de Gaar, A. T. den Boer, M. J. Munters, E. E. Blaak, and A. Duijvestijn, “Monocytes, but not T cells, respond to insulin with Akt(S473) phosphorylation independent of the donor glucometabolic state,” *Diabetes/Metabolism Research and Reviews*, vol. 30, no. 4, pp. 323–332, 2014.

[43] R. C. Bunn, G. E. Cockrell, Y. Ou, K. M. Thrailkill, C. K. Lumpkin, and J. L. Fowlkes, “Palmitate and insulin synergistically induce IL-6 expression in human monocytes,” *Cardiovascular Diabetology*, vol. 9, no. 1, p. 73, 2010.

[44] C. Shi and E. G. Pamer, “Monocyte recruitment during infection and inflammation,” *Nature Reviews Immunology*, vol. 11, no. 11, pp. 762–774, 2011.

[45] D. C. Macias-Ceja, J. Cosin-Roger, D. Ortiz-Masia et al., “Stimulation of autophagy prevents intestinal mucosal inflammation and ameliorates murine colitis,” *British Journal of Pharmacology*, vol. 174, no. 15, pp. 2501–2511, 2017.

[46] X. Bian, L. Chi, B. Gao, P. Tu, H. Ru, and K. Lu, “Gut microbiome response to sucralose and its potential role in inducing liver inflammation in mice,” *Frontiers in Physiology*, vol. 8, p. 487, 2017.